<SEC-DOCUMENT>0000950170-25-045729.txt : 20250327
<SEC-HEADER>0000950170-25-045729.hdr.sgml : 20250327
<ACCEPTANCE-DATETIME>20250327073009
ACCESSION NUMBER:		0000950170-25-045729
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250327
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250327
DATE AS OF CHANGE:		20250327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CalciMedica, Inc.
		CENTRAL INDEX KEY:			0001534133
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				452120079
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39538
		FILM NUMBER:		25775303

	BUSINESS ADDRESS:	
		STREET 1:		505 COAST BOULEVARD SOUTH
		STREET 2:		SUITE 307
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-952-5500

	MAIL ADDRESS:	
		STREET 1:		505 COAST BOULEVARD SOUTH
		STREET 2:		SUITE 307
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CalciMedica, Inc. /DE/
		DATE OF NAME CHANGE:	20230322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRAYBUG VISION, INC.
		DATE OF NAME CHANGE:	20170717

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRAYBUG, Inc.
		DATE OF NAME CHANGE:	20150303
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ck0001534133-20250327.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-26T20:39:30.0914+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ck0001534133="http://www.calcimedica.com/20250327">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_265d8cb2-1445-471f-8432-7ff8b7624fc9" name="dei:EntityCentralIndexKey" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be">0001534133</ix:nonNumeric><ix:nonNumeric id="F_de3710dc-e6db-4a09-ad63-a2b8e0102b44" name="dei:AmendmentFlag" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be">false</ix:nonNumeric><ix:nonNumeric id="F_bcfb88c7-791f-4349-8638-5d1e4d9827f8" name="dei:SecurityExchangeName" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be">NONE</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ck0001534133-20250327.xsd"/></ix:references><ix:resources><xbrli:context id="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-27</xbrli:startDate><xbrli:endDate>2025-03-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7aedebb8-67e5-461d-a4ab-a2ccbac6ad1b" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_d5bef944-5f6f-46dc-8aec-016faa459175" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 27, 2025</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0170a5b-da27-4cf1-ae25-0054ad12caca" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CalciMedica, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:18%;box-sizing:content-box;"/>
    <td style="width:41%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b4f12da2-08bf-445f-8d62-8f92ab44e5e5" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2ed06d9a-7633-4833-a181-454c1b5a180f" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-39538</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1ba79f07-19fe-4adb-9bad-2fd6dabc7982" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">45-2120079</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_62dbdf2e-f723-40f3-b3bd-1c2e679d8159" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">505 Coast Boulevard South, Suite 307</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6d455063-c512-4894-a9a8-eee236194afb" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">La Jolla</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_f4dc6bb9-af4c-4830-8dd8-67bb0e635c8c" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5b084aa3-3056-4452-b769-88f253a02229" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92037</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_04ac3a63-3b25-4bc2-b1db-1468c042a381" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(858)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_6c886ca3-94f9-4289-bc05-ad325e81281e" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">952-5500</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f3f2892f-a9be-4e60-9f15-9c62079fc036" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Not Applicable</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab3c04f4-da5a-42bc-b794-5698ddfff292" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_901acf24-a0e9-4d3c-9e78-081b8e41d9b4" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_406e7715-9d36-4d0f-af2e-015410a21ee9" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87c87279-90b6-46de-bfe2-c0496d6543ed" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b1275da8-8f05-45e5-9242-d6ce9e81860e" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b047843e-7887-411e-aac7-d797dcf7aad6" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CALC</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_bcfb88c7-791f-4349-8638-5d1e4d9827f8;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Capital Market</span></span></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_17551bc6-0df0-4d90-ab0a-2b2cef9fd39d" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;"><ix:nonNumeric id="F_49eca329-7e58-4520-82ea-11130916fe2f" contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02.             Results of Operations and Financial Condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 27, 2025 CalciMedica, Inc. issued a press release announcing its financial results for the fiscal year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01.            Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(d) Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.14%;box-sizing:content-box;"/>
    <td style="width:4.08%;box-sizing:content-box;"/>
    <td style="width:88.78%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="ck0001534133-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release dated March 27, 2025</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:44%;box-sizing:content-box;"/>
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:41%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CalciMedica, Inc.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 27, 2025</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">/s/ A. Rachel Leheny, Ph. D.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">A. Rachel Leheny, Ph. D.<br/>Chief Executive Officer<br/></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ck0001534133-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Exhibit 99.1	</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img205673473_0.jpg" alt="img205673473_0.jpg" style="width:303px;height:59px;"></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">CalciMedica Reports 2024 Financial Results and Provides Clinical &amp; Corporate Updates</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Segoe UI',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Segoe UI',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Enrollment ongoing in Phase 2 KOURAGE trial of Auxora&#153; in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Segoe UI',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Segoe UI',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Post-hoc analysis of subset of patients with AKI in t</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">he Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Segoe UI',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Cash position expected to fund operations into mid-2026</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">LA JOLLA, CA, Mar. 27, 2025</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2013; CalciMedica Inc. (&#x201c;CalciMedica&#x201d; or the &#x201c;Company&#x201d;) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the year ended December 31, 2024 and provided clinical and corporate updates.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;Enrollment in our Phase 2 KOURAGE trial is on track to deliver data around the end of 2025,&#x201d; said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. &#x201c;Looking ahead to the KOURAGE readout, we are further encouraged by the promising readthrough from the data recently presented at the 30</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> International AKI &amp; CRRT Conference, which show a 62.7% relative reduction in mortality in CARDEA patients with both kidney failure and respiratory failure, mirroring KOURAGE&#x2019;s patient population. With the proceeds from our recent credit facility with Avenue Capital, we have ample runway to get through our KOURAGE data readout based on our current enrollment projections and engage with the FDA on the design of a Phase 3 program in acute pancreatitis with SIRS in the next few months.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Recent Clinical &amp; Corporate Highlights:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Updates &amp; Anticipated Milestones</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Acute Kidney Injury (AKI) Program Update</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Enrollment ongoing in Phase 2 KOURAGE trial: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Enrollment is ongoing in KOURAGE, the Company&#x2019;s randomized, double-blind, placebo-controlled Phase 2 trial of Auxora&#153; in patients with severe AKI with associated acute hypoxemic respiratory failure (AHRF). CalciMedica expects to enroll 150 patients with stage 2 and stage 3 AKI who have AHRF and are receiving oxygen either by non-invasive mechanical ventilation, high-flow nasal cannula, or invasive mechanical ventilation. Data are expected around the end of 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Post-hoc analysis of patients with AKI from the Phase 2 CARDEA trial in severe COVID-19 pneumonia: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In March 2025, Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica, </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">delivered a plenary presentation at the 30</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> International Acute Kidney Injury and Continuous Renal Replacement Therapy (AKI &amp; CRRT) Conference. The presentation outlined the multi-faceted role of CRAC channels in AKI pathophysiology as well as new data based on a post-hoc analysis from the previously completed CARDEA trial, which included 38 patients who were enrolled with AKI in addition to respiratory failure. Within this subset:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Patients treated with Auxora showed a 62.7% relative reduction and 29.3% absolute reduction versus placebo in mortality at day 30 which persisted through day 60.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">7 out of 15 (46.7%) patients on placebo died by day 30 and day 60 as compared to 4 out of 23 (17.4%) patients on Auxora.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Acute Pancreatitis (AP) Program Update</font></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) planned:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> CalciMedica plans to hold an end-of-Phase 2 meeting with the FDA around the middle of 2025 and expects to be in a position to initiate a Phase 3 program in AP and accompanying systemic inflammatory response syndrome (SIRS) around the end of 2025 pending additional funding.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Plenary presentation delivered by a collaborator at the American Pancreatic Association (APA) 2024 Annual Meeting: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">CalciMedica collaborator Prof. Robert Sutton, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust, delivered a plenary presentation titled &#x201c;Auxora Decreases the Development of Severe Organ Failure in Patients with Acute Pancreatitis and SIRS&#x201d; at the APA 2024 Annual Meeting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Asparaginase-induced Pancreatic Toxicity (AIPT) Program Update</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Enrollment ongoing in Phase 2 portion of CRSPA trial:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Enrollment is ongoing in the Phase 2 portion of the Company's CRSPA study in AIPT, with over 50% of the study enrolled. CalciMedica expects to provide an update on this study in the second half of 2025.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Updates</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Leadership team strengthened with CFO appointment: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In November 2024, CalciMedica announced the appointment of Stephen Bardin as Chief Financial Officer and the previously planned departure of Daniel Geffken, Interim Chief Financial Officer. Mr. Bardin has extensive experience in capital raising, corporate development, and strategic finance, and most recently served as Chief Financial Officer of atai Life Sciences. Prior to atai, he was Senior Vice President of Finance and Operations at BridgeBio.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Key addition to Board of Directors: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In January 2025, the Company announced the appointment of Alan Glicklich, M.D., to the Company's Board of Directors. Dr. Glicklich has more than 20 years of experience in the biotechnology industry and currently serves as Chief Medical Officer of Nuvig Therapeutics. Previously, he was Chief Medical Officer of Chinook Therapeutics. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Other Business Highlights:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">On March 5, 2025, CalciMedica announced a credit facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, providing up to $32.5 million. The credit agreement, which has a term of 3.5 years, includes an initial tranche of $10 million fully funded at close and additional tranches of up to $22.5 million available to the Company subject to certain milestones. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2024 Financial Results:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cash Position: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cash, cash equivalents, and short-term investments were $18.7 million as of December 31, 2024, which, combined with the net proceeds of $9.7 million from the Company&#x2019;s recent debt financing announced in March 2025, the Company expects to be sufficient to fund its current operating plan into mid-2026.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">R&amp;D Expenses: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Research and development expenses were $14.5 million for the year ended December 31, 2024, compared to $15.9 million for the year ended December 31, 2023. The decrease of $1.4 million was primarily related to a decrease in personnel expense of $3.3 million, driven by one-time charges as a result of the merger with Graybug Vision (&#x201c;Merger&#x201d;) for the year ended December 31, 2023. This was partially offset by an increase of $1.3 million in chemistry, manufacturing, and control activities related to the Company&#x2019;s Phase 2 clinical trials of Auxora, costs related to preclinical studies of $0.3 million, and consultants and other costs of $0.3 million.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">G&amp;A Expenses: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative expenses were $9.7 million for the year ended December 31, 2024, compared to $22.2 million for the year ended December 31, 2023. The decrease of $12.5 million was primarily related to a decrease in personnel expense of $13.0 million, driven by one-time charges as a result of the Merger for the year ended December 31, 2023. Additionally, professional services decreased $0.2 million due to increased costs related to the Merger for the year ended December 31, 2023. These costs were partially offset by an increase of $0.7 million in consultants and other costs.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Other Income:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Other income for the year ended December 31, 2024, was $10.5 million, compared to $3.7 million for the year ended December 31, 2023. The increase of $6.8 million was due to the fair value adjustments to CalciMedica&#x2019;s warrant liability of $9.5 million as a result of the 2024 Private Placement, compared to fair value adjustments to its warrant liability and convertible promissory notes for the year ended December 31, 2023, and due to an increase of $0.4 million of interest income on the Company&#x2019;s cash equivalents and short-term investments for the year ended December 31, 2024, as compared to the year ended December 31, 2023.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net Loss: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net loss was $13.7 million for the year ended December 31, 2024, compared to a net loss of $34.4 million for the year ended December 31, 2023.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">About CalciMedica</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora&#153; has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO &#x2013; </font><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">NCT04681066</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS). The Company has also completed a Phase 2 trial (called CARDEA &#x2013; </font><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">NCT04345614</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE &#x2013; </font><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">NCT06374797</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) with data expected around the end of 2025 and continuing to support the ongoing investigator-initiated Phase 1/2 trial (called CRSPA &#x2013; </font><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">NCT04195347</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) with an update expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit </font><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">www.calcimedica.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">This communication contains forward-looking statements which include, but are not limited to,   CalciMedica's expected cash runway; CalciMedica&#x2019;s planned and ongoing clinical trials and the timing, design, expected patient enrollment thereof and the expected timing for the release of data from those trials, including its  Phase 2 KOURAGE trial of Auxora in AKI with associated AHRF; its ongoing Phase 1/2 CRSPA trial of Auxora in pediatric patients with AIPT; plans for an end-of-Phase 2 meeting with the FDA  for CARPO and to be in a position to initiate a pivotal trial in AP around the end of 2025;  the potential benefits of Auxora for the treatment of AP,  AKI and AIPT; the potential of CalciMedica's proprietary technology to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases; and the potential of additional proceeds from the credit facility with Avenue Capital Group if certain milestones are achieved. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. CalciMedica's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the impact of fluctuations in global financial markets on CalciMedica's business and the actions it may take in response thereto; CalciMedica's ability to execute its plans and strategies; the ability to obtain and maintain regulatory approval for Auxora; results from clinical trials or preclinical studies may not be indicative of results that may be observed in the future; potential safety and other complications from Auxora; the scope, progress and expansion of developing and commercializing Auxora; the size and growth of the market therefor and the rate and degree of market acceptance thereof; economic, business, competitive, and/or regulatory factors affecting the business of CalciMedica generally; CalciMedica's ability to protect its intellectual property position; the impact of government laws and regulations; and CalciMedica&#x2019;s financial position and need for additional capital. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#34;Risk Factors&#34; in CalciMedica's Annual Report on Form 10-K for the year ended December 31, 2024, being filed with the Securities and Exchange Commission (SEC) later today, and elsewhere in</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">CalciMedica's subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at </font><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">www.sec.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">. These documents can be accessed on CalciMedica's web page at </font><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">ir.calcimedica.com/financials-filings/sec-filings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">. The forward-looking statements contained herein are made as of the date hereof, and CalciMedica undertakes no obligation to update them after this date, except as required by law.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Contact Information</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Argot Partners</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Sarah Sutton/Kevin Murphy</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">calcimedica@argotpartners.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(212) 600-1902</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">CALCIMEDICA, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_balance_sheets"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Balance Sheets</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(in thousands, except par value and share amounts)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.967%;box-sizing:content-box;"></td>
    <td style="width:1.48%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:13.037%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1.48%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:13.037%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br>2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br>2023</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,935</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,530</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,734</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,708</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid clinical trial expenses</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other prepaid expenses and current assets</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">248</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,665</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,605</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">413</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,794</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,185</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#x2019; Equity</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,998</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,419</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial costs</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">820</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,141</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">866</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,468</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,684</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,028</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term liabilities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant liability</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,700</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,384</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,028</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 9)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#x2019; equity</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $0.0001 par value; 500,000,000 shares authorized at December 31, 2024 and December 31, 2023; 13,481,917 and 5,754,505 issued and outstanding at December 31, 2024 and December 31, 2023, respectively</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,166</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,218</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(159,764</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(146,064</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#x2019; equity</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,410</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,157</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,794</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,185</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">CALCIMEDICA, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_statements_operations"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated Statemen</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">ts of Operations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"></td>
    <td style="width:1.58%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:12.923%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1.58%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:12.923%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,478</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,859</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,726</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,216</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,204</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,075</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(24,204</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(38,075</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of financial instruments</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,490</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,168</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,014</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">550</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,504</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,718</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,700</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(34,357</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share - basic and diluted</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1.22</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(7.66</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of shares outstanding used in<br>&#160;&#160;&#160;computing net loss per share&#x2014;basic and diluted</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,245,915</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,486,258</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img205673473_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img205673473_0.jpg
M_]C_X  02D9)1@ ! @$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "' K8# 2(  A$! Q$!_\0
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MZ\(2=*FZ=*+A5Q%.K3Z<-0]LVY74(Z-IV;EH[+?O=^7J?9/[:O\ P6D_;/\
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MSR!\./'X.,],_P#"W#CCC.#ZXK^>$G))/4\FBO\ 2/ASP.\,^&LIPF4X7AC
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M3_X(-?#7Q1\-/ 7[3G[9VEZGXFN_'.DWVO>$?@!?1W^AZ+8>&M8M!;^&M?\
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MU*&!VN!:F^CGC0O.L6-\H/\ JI^"?A_X#^&NB_\ "-_#GP3X1\ >'?M<]_\
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M/*\+A:?LY4E.K7A3YL/5KXXET'RRI:2DKM17NV\U]F7DEZVT;_GK_P"#BO\
M;7^*G[.DO[-GP_\ @)\9_&_PM^(6JQ>-_&?BZT\'W-]I0U3PA=R:3H?AFXO]
M26W:QNO*U?2/$\<%@)FN("KW$L21S6[OXO\ \&\W[0G[8O[47[07QK\3_&7]
MHKQI\1OAM\+OA=INEW?@OQEKU[J+7/BKXA>(EF\-Z_I=L+/[$!HNG^!_$UI?
M37%U#.G]MV:VL-RDERUM^;__  <6?&*]^(W_  4$U;P0-2T#4M!^#/@'PCX-
MT5]&0->6=QJ6GIXK\1:;KMVEU/'<:I8^(M=U*!HUBM6LH!#930F>"663]O/^
M#9?X-S>#OV//B5\7=5\+66GZC\7_ (NZC%H'BI6B?4O$/@?P+I.G>'K>RF,<
MKM#8:-XV7QPEI#-'%*US=7\W[R&2%J_0\VRO*N&/H]8"O6RW+GG&<8'!1HXZ
MMA,%4QJJ9YF,LQ:AB:E"&(YZ>5.K&$82E5PZA[LG"BZBVE&-/!JZ7--*SLF_
M??-OO\/JUZ'[M_M*>-[SX;_L_?&;QSIFJ6FBZQX9^&OC'5-!U&]\AH(?$,&A
MWO\ 8*>5<AH+B:XU<V5M;6LBN+JXEBMPCM*%/\:/P8^'R_%OXO\ P\^&TNH'
M3(_'7C;PYX5DU(1^<UG'KNLV>E-=K&.)'@6Z\Y4/RNR!3A6)']-'_!6OQK;>
M%OV/M=T.?3KB]D^(GC3P9X3M+F&2)(=+N-.U)O'C7MTLA#2Q2VO@RYTZ..$-
M(+F^@F($44A'X>?\$S?!.G^-_P!L;X46^JV-]>V/AZ]U?QB7LS,D=G?^$] U
M37="O+Z6)&6.SB\1V6C(PE:.*>>6WM"^ZY5'_P ;?I S_P!9_%[P_P"#5:M0
MA')\/7HSJ5X4U5X@SM4L5":C']WS8'"X6=2O1YI.$XIM2H)+_4'Z'-)\"?1P
M\8O$R7-A<74GQ)B\+B:='"U*[PW"'"_M\OK4Y5)M5G3S;'YA3HX3%*,%6IR<
M8RABFY>4_M2_ S7/V4_V@?$7@9'N/L&E:G'XB\"ZK(ZRS7_A6]N9;G0;IYC!
M"LM[:Q1MINHS"T@B;5;&]:WA$ B)_J=_8O\ VBK#]I;X%>&/&QG0^*M+AB\-
M^.K0RPO/%XDTVWA6;4'2&WM(TBUZV:#6(EBM8;>"2[N+&'?]B=C\P?\ !53]
MFFW^+WP1D^)GA[2OM'C[X4AM162SMT:]U7PE/(BZSI\[^=$TL>F@_P!K6P$5
MU-'Y=W' B+<S-7Y%_P#!,7]I>7X&_'6R\)Z_J8M/A_\ $^2W\/ZZMR^VUL-5
M4S_V#JQ,D\<=NUM?7!AN94BEE>RN;F((249'D=2?@1XUXK(*\W2X*XU=#ZI.
M3:H8:ABL15CE=>4YM14LGQT\3EF);ES?4:[Q=1-RHHCBRC2^EK]%S <7X2G#
M$>*7A;'%+,:4(WQ6.Q. P>'EGV&A3A>4X<2952P6>8*,:?*\VPJR^@XJ.(;_
M *PZ_%S_ (**_P#!1B#X:0:Q\#O@9K$<_P 0;B.?3O&?C;3IUDC\%QN&ANM%
MT2YB8@^*""T5[?QM_P 2#Y[>U8:V'FT;UG_@HA^WAH/P \*ZO\+/ .HQZC\9
M/$VF2V<LEC<*5\!Z;?P[)-2O)8R6CUV>VE8Z3:*RS6?F1ZI<% MG#>_@C^RI
M^RE\1_VNOB,=(T87%EX<M+F.^\<>.;^.>XL=&LYYBTI,LCA]0UB\Q(MA8"<7
M%Y,'>66&VBN[RV^T\:?%?-:F8TO#'PXE4QW$N9S>"S7&9;)SQ. E4O%Y7@JL
M&H4,=*GSU,PQKJ1658:,[SHU_:5L'^9?1>^CUP_1R:OX[^-L*&5<"9#269\/
MY;G<52P6;J@U*.>YIAZBE5Q651K.G1R?+%1G+B#&SA:EB,'['#YGY=X/^#/Q
M ^)'@;XJ?%BTMV_X1/X8Z=INJ>)_$6I&Y6WNM1UWQ%H^@V&C65PMO.+O6;J7
M5VU V[-%'%8V5U-<7$3M:0W>Q^RMX%_X63^T9\%_!DOA^;Q1IVL_$?PFNNZ)
M%%-*MWX8L]8M=1\5-=+ \<HT^U\-V>K7FI2+(GE:?;W,I8!#7[*?\%*_"WP]
M_9>_9%^%_P"SY\,M*U+1+/Q7XWDU>_O[.=89/$D?A'1C#K-WXRN87MY-8O=2
MU3Q%X>O;:WEADL;8Z3;K:06<&DZ;!%\=_P#!('P3IOBC]K)->U :@)OA[\/O
M%GBK2)+1S':?VO>/I/@Q8=3;RI$EMY-'\6:W)#;>9#))=P07",Z6DL;?SG6\
M.*.2>*/!/ 53$0QF93K<.SXHJ0FJF%AC<;BI9GC,-A(U:-I4<-DT\-3A[6$H
MXNJI5I1IQKNC3_MC"^-V)XI\ O%3Q?H8.KEN1T\/QG2X"H3INAF$\LRO+Z>1
M9;CL?4H8EN&)QO$\,?6G]7J0EE]!T\-3E7GA/K-?^J!5"J%4850% '0 # 'X
M"O@_]LG]O3X;_LF6,.B2V[>,_BEK%C)=:/X+T^ZABCTRW>-_LFK>++O>TFEZ
M9<3*%M8(89]1U *[V]NENDEU'[O^TU\<M'_9T^"GCCXK:J(+B?0-,:/P_I<\
MA0:WXGU!UL= TH!&$YBNM3GMQ>RVZR26=@MU?,GDVTC+_&Q<W'Q%_:!^*DD\
MK:GXS^(OQ(\3#:GF>??ZKK.L7:Q6]I;>?(L<2&66*TLK<O%:VL*PP(8;>)=G
M]5^.OB[C>!*. X;X7C"KQ9G5-585?9+%2RO!3K?5Z%6EA'"<<3CL?7C5H8&E
M.,X0=&K4G2J/V-.?^?'T2_HX99XM8G-N../)U,/X=\+5Y8>K0^L2P-//\TI8
M:.,Q6&KYC&K2G@LJRG"5,/BLTKTZE*K46)P]&E7HQ^LU:7T!\6/V^/VK_C-K
M1O\ 4?BIXF\+6:22O8>&_AM?ZCX(T:PCFCABEB7^P[R'6-1B80JY;7=6U9XG
MDF\F2&.0QU\PS^&/'5U-+<W6BZ_<W$\C2SW$]G=33S2N2SRRRR(TDDCL2SN[
M,S,2S$DDU_5%^R)_P3G^$?[/V@:=KGC31-)^(GQ4N[6QN]0U?Q!I]MJ&E>&;
MQ[*W:\TKPYIMP]W8/]EO_M!77YXGU&X"Q-:FPA7R6_1VOS#+OHW<:<7X2&<<
M?<<XO"YMBG]8^HXBA7XAQ.%55+FAB<37S3"T*-;EA2B\/A%5HTHQC253]VH1
M_><Y^F]X7^&^85>&O"'PFR[,>'<O7U/^U<)BL'P;@\>\._=J8+!87(,QQ6*P
MKG.O*.+S&6'Q.(J3GB)4+UI5)_Q)> ?VD_VD/@G=Z?#X*^*OQ!\*Q:$UQ%9>
M'Y=:OK[PU9FY5VN83X2UIM0\,DN)VE9)=)9DE<3KLF"2#^@[]@K_ (*0Z;^T
M7./AE\7O[#\*_%\-*^@W6GH^F^'O'=HBM(;?3X+NZNC8>);2-6:?3/M+Q:G"
MK7>F+&Z3V-O]=_M!_L>? S]H[0M6LO&?@W2;'Q3?6]Q_9_C_ $.QM].\5Z;J
M4JVGDW\]]:K VNQQM86D<MAK9O+::T22VB^S-()T_D#\;^%O%GP*^+.M^&;B
MY;2O&'PV\7SVJWNGW*2O8:UX=U,^3=6EU"2KM;W=JD]M.IPX6.4## 5X694?
M$;Z.&=Y1B_[=J<3<&YE7GA_J<ZV*A@L1"A"G[7"5,#B*F(IY1F<<-:I@<1@Z
MU6%6-"U256A1KX4^LR/$^"GTW.%>),N7"5#@3Q,R3"T\:LRI8? 5,SPE7%U*
MGL,PHYK@Z&#J\19'+&J5#-<%F.&H5:,L7STH8;%XG"9@?W05#<7%O:6\]U=3
MPVUK;0RW%S<W$J0V]O;PHTDT\\TC+'%#%&K22RR,J1HK.[!02/ ?V5?C*OQ^
M_9_^&?Q4<K_:7B+P_'#XA6.U>SMX_%.C3S:+XGCLX9'E862:[I]^MF_F.)+<
M1OG)('Y>_P#!8/\ :?OO#&A^'?V<?!6M7%CJ?BJS/B;XES:==20RKX5=[BRT
M+PK<20AE:'Q!?0WVIZO9F:WNHK'1M+AN8I]+\0LLG];<4^(>2\,\"3X[<OKF
M KY?@L9E-",U2J9G6S.G2EEN&IRM4Y'6]M"=:HH5/88>%:NX3C2DG_G1P!X,
M<4<=>+5+PDC'^S<XPN<YGEG$.+J4IUZ.18?(:U>GG>-K0O2]HL*L-5IX:E.I
M06+QE3"X2-2G/$0:X;]L#_@KAJ]IK6O?#O\ 9@73XK/3;E+&?XP7D4&J/J$\
M'VA-0'@_0[ZTETT6"SBV2SU_55OTU"*.Z>VTE+:>SU!_QH\9_%7XT_&>^#>.
M/'7CSX@W$FH7^I6MGK6N:OK%C:WUYNN+Z32=(FN)-+TH,BL3;:39V<$-O&(H
M88[>-47W+]C+]CSQC^UMX_?2=/F.B>!?#CV5YX\\6NJ2_P!DV%W+.+6SL+9V
M'VS6]8^QWL.E6[ 6X-I>7=W(MM92I+_59\&_V9O@?\!-*T[3?AI\/M!T>[T^
M+9_PDUS96^I>,+V62QM]/NKF]\37D4FJL][;6T:W-O;SVU@2THALX4E=#_(V
M0\)>*7T@:F)XAS_B*KDO"T\34HX2$X8AY?4C"N_:T,FR6C6P]'$TL'*'L:N8
M8RNJE2O2C2EB<56HUW0_T<XN\1? #Z'-+ \&\(<%8?BGC^E@J.(S&M"I@HYS
M1G4PD?8XOB7B?$X7&8G XC,XS^LT,HRS".C0PM>>(IX' 87%818O^,?1[GXG
M?#V_A\2^'KOQEX+U2V+0V^NZ%>:OX>U& W"/"\4.IZ9-9WD?G1N\;I'.HD0L
MK!E)%?H=^RW_ ,%2?C=\(=;L=%^+>L:K\7?AU(EO836VNW5NWBO0$-XTD^J:
M;XDFM7U+5YUBGF66Q\17MY'.L5O#!>Z:D;.W]1'B#PWX=\6:9+HOBG0-%\2Z
M-.\4L^D^(-+L=9TR:2"02P22V&HP7-K(\,JK)$[Q,T<BAT*L :_ W_@I/_P3
MU\&>!_"-]\>_@CI4/AO2=&>SC\<>"+4SOIUO#>W45C;^(-#-Q-*UG!]JGM[7
M4=*#BVB>>&ZT](8_M-NWI9[X->(?A%@JO%W W&>(S'#Y/3GCLRP5'#ULMJ_5
MJ:4L56J9;+&8_+\TPE.C353%TJ\HU52I>TITJDJ47#P^$_I-^#'TCLUP_ASX
ML>&&"R3%\25:>4Y'FF(Q>&SNC]>K/DP&%HYY#+<HSG(<PKXFM.CE^(PD9T'7
MK^QK8BA3Q%15?G;_ (*T_%SP;\5?C1X F\%:J-:TO1_A9X=<:E;30W&EW)\1
MW&H^*8)-/F@FE23.F:QI4=XV$9;N![60%[,X^V_^")G@JPL_AC\9?B(L]V=4
MU_QQI'@R:U8Q?84TWPGH,&N6=S"!&)C=3W?C348;@O*T0AM;41QJYE9_YRLE
MB,DDX &3G '  ST [#H*_L"_X)K>"=1\#?L:_"&SU:UL+>]U^QUCQH'L7AF-
MUIOC#7-1U_0KB\GA1#)?'0[[3HIXY2\MIY2V+.1;*!P>!V,Q7'_C?FO&F/PU
M.A5I9=F><3ITHSJ4,/B,12PN2X:A3JMQ<9+"XJLXSG%^T5&K[BE+FA[/TK<L
MR_P>^BIP]X7Y1CJ^*P^)SG(N&J=7$SI4<7C<)@\1CN*,=C*U",9J=/\ M# 8
M=3I4I05"6)P[]K*-/DJX7_!3;XV:_P#!']F*_P!3\(ZIK_A_Q?XO\8^%O"?A
MOQ'X>GAM;C1+I+F?Q5J4]S/)(LJ6M]X?\,:QI'^C1S3-<:A KHMN9I8_R,_8
M$^/G[2GQN_:D^&?@[Q7\=OB/>^&H=0O_ !%K6GS7[ZA9:I9^&='U'Q =)U&/
M$4<5AJ\NFQ:5=32EE6*]*QHUPT /O'_!;7XA1R:E\$OA;9:Y<B6SL?$_CKQ%
MX<166S(U"?3]!\(:Q.Y79-<JECXWLK9%?,$4ETTB'[1$PYW_ ((F^#-2N/'_
M ,8OB"EQ:+I&C>"],\(W%HQE-]+J'BK7K75[*>(!?)%K;6_@K48[DN_F-+=V
M?E*568K]+Q;G.;<3?23R3AG YMF='*\JQ>2X;%X3 X[$4<)B*66X27$>90K4
M<+BJ$*CFJE;!XFI5O6IJG*#A.-&%*7PGAUPQPYP+]![BKCO-N'<CQ6?\08#B
M;'9=F.:Y3@\3F.#KYYF-'@G)*F&Q.88#%5:*I2HX;,\#2H6PU:=6%:%2E/%5
M,1'^B>ORO_;6_P""F/@_]G6]U/X<?#6QL?'?Q:MHD6\EN)/.\(>$+EV):VUQ
MK.[M[S4M5C0*7TBRFMA!YA%Y?V\\1M9/:/\ @H'^TU_PS5\"-6U/1;B%?'OC
M-I?"W@Z)GD6:VN+VWD6_UI/))EB;2+(R7-K,X6$WJV\;2!V56_E;^#WPD^(/
M[1_Q2TOP)X0ADUGQ5XHOI[J\O;ZY(CMX<O=:IK&IWD[.ZP6L GN[J9O-E*1O
MY<<\Q2&3[+QS\7LYX=Q^#X#X&C*IQ3FD*'UO%8>BL5B\#''2]E@<!E^'Y)QE
MFF.<E452<92PM"5&=.E*IBJ5:A^8_1/^CAPUQIE.9^+GBM*%'@#(*F*> R_&
MUW@,OS:>506(S3-<WQBJ4JD<ARN,71E2I2A#'XJ.)IUJ\:.!KX;%]Q\3/VP_
MVG/C#?ZG=>+OC!XYEM-2LYK"[\/^']9O?#/A@Z5*TQDT^7P]X=DT[2KJT*3O
M#*^I6][=7$.V.\NKD(I'AP\*>,I )!H&LN) '#BPG8.&^8,&$9!# Y!!YSFO
MZTOV<?\ @GA^SY\!="M_[0\)Z/\ $GQM<V,,6M^)_&NE6&MVPN62W:[A\/Z+
MJ%M-8:38&XMT>&1XKG5F48GU%T;R4^\41(D2.-%CCC54CC10B(B *B(J@*JJ
MH"JJ@!0   !7PF7_ $8^+>)*$,SXXXYJ8?-:\55EAY4,3Q'B*$JK<JE/$8[%
M9GA(>UTA[2.'5:ESJ2C6J*,9R_7<W^G?X<<$8JID7A5X34<9P]A)NA#&0Q>!
MX*P>+C0C&%*M@LIP.19E46';=54IXQX;$.GR3GAJ,YSI0_B@^&/[6G[2GP8E
MLAX#^+WC?1[&QTUM+L=!O]4EU_PQ;:9)<07+6]CX8\2)JWA^R4RVL8BNK#3;
M>[MXFGAM;F&*YN%E_H<_88_X*0>&_P!IFX3X<_$:RTGP-\7XK:-]+BM;IT\.
M^/TM[-'U&705O&,VFZW!+'<W<OAF:YOI)-, O-,O[\6NJ0Z;Z=^U%_P3X^!W
M[07A'58]"\*^'/AQ\2H[1'\.>,_#>DPZ1:_;+234+F&Q\2:3I*6]EJFF:A/J
M5TM_>_8WUFW,D%U;W,PLH[&;X^_8C_X)7WOPN\8Z)\6_C_>Z9?\ B#PS>P:O
MX1\!Z+>->6NE^(M)U:6?2?$&OZQ:LEM>'3VL[#6='TS3GEB-[);3ZI<H;*?2
M)O3X0X*\;_#7C?*,GRW'/B?A'&N$\;5Q.+KK(</E]*<:6*56EBY5L1DV9X>G
M4C5PE/ 1J_76J<8K&T:.+HT/!\2/%+Z*OCEX5\2<2YYE,>!/$?*XU*>58? Y
M=A'Q;C,YKTIU\ Z%;+X8?"<2Y%C*U&>'S"KFTL.LLBZ\YRRS$XK+\3C/VXK\
ML/VX/^"E7AO]FS4IOAM\-=,TGQ[\5E@E_MDWEY+_ ,(WX&DDA)LTUA;'$^K:
MPSM'++H,%WI[6UL0][?6\LD4$GN/[?\ ^TE_PS9^S[X@US1K];3Q]XO+^#O
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M^\6ZA+H>HQ16QU*TU"UT6VL;/4Q;0)+IVK7D<T%OJ-I/:P^X_MF?\$Y?A?\
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M\.0_%7_1>_#_ /X1FH__ "XK]<_UH^E7_P!$1D/_ (!E/_T5_P!7?E;^</\
M4']GU_T=;B[_ ,#S_P O^K?_ -7?;3[A_P"'MW[('_06\=_^$E'_ /+>OP*_
M;L^,/@#X[_M'>,/B5\-?M9\+Z[9^&Q!)?:;%I5W+>6'AK1]-U&6XMHI9@9)+
MZSN&,SR-),"LCG+5^BG_  Y#\5?]%[\/_P#A&:C_ /+BC_AR'XJ_Z+WX?_\
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MX1\.W7G)/-::9IT-M=ZPQ@:#=937%S<6<,<L<^^6W2Y1E$<WS?E;_P %(?\
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M'AO5EC2WU?1-4MO+NK"_MC@H_E7$=M=Q7%M#^MG[(G_!PG^V3^S?H'A7X?\
MQ$T_PI^T5\.?#*0:?;Q>-FO]$^)-MX>L=*_L_3M"TWXBZ2UQ')%:3QVUU_:/
MBWPIXRU>6-);(WZ020&T_=O%OPCQG'6,P_&7!V+P>.Q&.P.&6)PL\73A0S"C
M1H1C@<;EN,DWAG*KAE3HSI5:E&A)4Z=:-;GG53ZL1AW5:JTVFVE=-Z25M'%[
M;=[+K<_T Z^#/^"B7[=OPS_8'_9Z\4?$WQ9K.DM\0]8TC7-)^"G@*Z62]O\
MQW\0DTUSI,,NE6E]IU^/"&BWUQI]]XWUN.]LHM)T=Q;V]T^O:IH.F:E_,Q\6
M_P#@Z+^/&O:9I]K\%/V;/AG\-M2#7ZZSJGCSQ7XA^*HGAFMXX]/;1;#2M.^%
M\&EW=E/YUQ+/J4GB"UN\P0G3X4CE:?\ &S7F_;%_X*4>(OC'^T+\6?'EWXMT
MSX)?#/5O&/Q"^)_Q!U"W\.?#[P)X?TNWO[GPMX"T)+*RM_#^CZ[X^\3./#GP
M_P# OAS3(+GQ'XIUB:\^R+ FNZS:_ <)> .<T\90S/CZK@LCR+"5:53$X18[
M#XG&XV;KQI4,%[3"RKX2C3Q=5TZ3E'$5,35]M##X:@\153I94\))-2JM1@K-
MJZ;>ND=--=MV]4DFWI\5^)_$WBCXF^.O$'C#Q/J5WXC\9^/?%.J^)/$.KW\P
MDOM=\2^)M5N-4U;4;R>4JKW>IZI>W%U<2R,JM-.[.P!)'^I?^QU\(O\ A0W[
M*?[/'P@F\,Z3X/U;P'\'_ >C>*O#^B+:#3K/QU_PCUC>>/YTDL"UI=W.I^-;
MK7]5U#4('D74M1O;K4#)*URTC?YH?[$WPPT3XT?M??LT_"?Q/;:I>>&?B!\<
M/AGX4\2PZ+(\.I'P[K'B_2;+7I;6X2*9K4P:1+>W$EX8F6SABDNGVI"S+_JG
M=*^C^DYF2IQX1R"BE3I0AF&9U:48N%.*BL/@<#&$8R4$J<8XV/*Z?N1<%3FE
M*<2\<[>S@M$N9VZ=$ONUZ:=.I_"#_P ',?CKQ1K/[<7@7P%J.I-<>%?!/P/\
M.:IX:TOR+>--.OO%^N:_)XAN!-'$MQ/)J#:'I8?[1+(L26D20K&-^_\ 0_\
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M@^9VQDFDT;Q/X:\1_:?^$>\0Z'KWV+R1>?V-JUAJGV0W'F_9Q<_8;B?R//\
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MC&<&X32FE*+<9)IM&2E*+O%N+[IM/[UJ?,'[-G[&'[+_ .R!8^);#]G#X/\
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MTZ=&>8YWF6,S7'SHT4XT:4L9CZV(Q$J=*+<:=-U'&";44D%>&_&7]FSX(_M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ck0001534133-20250327.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-26T20:39:30.5832+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.calcimedica.com/20250327" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:ck0001534133="http://www.calcimedica.com/20250327" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ck0001534133-20250327.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 27, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 27,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CalciMedica, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001534133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-2120079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">505 Coast Boulevard South, Suite 307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-5500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Not Applicable<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CALC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NONE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,,[>UI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( ,,[>UHVC)\W[@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%JPS ,AE]E^)[(3M@*)LVE9:<-!BML[&9L
MM36-8V-K)'W[)5Z;,K8'V-'2[T^?0(T.4ON(+]$'C&0QW8VNZY/48<V.1$$"
M)'U$IU(Y)?JIN??1*9J>\0!!Z9,Z(%2</X!#4D:1@AE8A(7(VL9HJ2,J\O&"
M-WK!A\_899C1@!TZ["F!* 6P=IX8SF/7P TPPPBC2]\%- LQ5__$Y@ZP2W),
M=DD-PU .=<Y-.PAX?WYZS>L6MD^D>HW3KV0EG0.NV77R6[W9[AY96_'JON!U
M4:UV0LB:2[[ZF%U_^-V$G3=V;_^Q\56P;>#77;1?4$L#!!0    ( ,,[>UJ9
M7)PC$ 8  )PG   3    >&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0
M>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$
M+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>
MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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MF*@JOC$4 R/3_+U^*8V1<7ZX813V@;T!KJ^D-(>!_510?NF9_ M02P,$%
M  @ PSM[6I^@&_"Q @  X@P   T   !X;"]S='EL97,N>&ULW5=M:]LP$/XK
M0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZ
MNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y
M*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB6
M2;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9
M,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8
MDMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*
MW5<D].)3"6T@L-5)](1&,80)"L2_C!9B7X2]_:VPI!&/QGWL_&[TH'_OC./W
MEE>B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0<O(%;2AZY
M=>)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%P<T:L#
M.EL)7(0;^A7N5WGF0/:=D$[H43N*LN3ZQ3GUX1W;^PO\*KY?7_**==+M9G!#
MS_(77HI.Y?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-W
MPQ-',)^ Q1' L#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/
M[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*P
MG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8
MQ?B,9AE2G0P^\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY
M_U=3_ 102P,$%     @ PSM[6I>*NQS     $P(   L   !?<F5L<R\N<F5L
M<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\
M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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MX_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0
M   ( ,,[>UI&QTU(E0   ,T    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ PSM[6C:,GS?N    *P(  !$
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M;',O+G)E;'-02P$"% ,4    " ##.WM:.JJBYT !   \ @  #P
M    @ ' $   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ PSM[6B0>FZ*M
M    ^ $  !H              ( !+1(  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ PSM[6F60>9(9 0  SP,  !,
M ( !$A,  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  7!0
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ck0001534133-20250327.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ck0001534133-20250327.htm">ck0001534133-20250327.htm</File>
    <File>ck0001534133-20250327.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ck0001534133-20250327.htm": {
   "nsprefix": "ck0001534133",
   "nsuri": "http://www.calcimedica.com/20250327",
   "dts": {
    "inline": {
     "local": [
      "ck0001534133-20250327.htm"
     ]
    },
    "schema": {
     "local": [
      "ck0001534133-20250327.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001534133-20250327.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001534133-20250327.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.calcimedica.com/20250327/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-25-045729-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-045729-xbrl.zip
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M/$%9V.E%.8U%TLNB <J /67!0-4L*R0^3+T(F2G/P*9/QS1ZT$Z*:#P8?@M
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M</D)EY^@@SHE>)XCLF92K.ECN#R1,&&$R2:8#*KD^T1FD]C"<:3!P0T;D)F
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MX6'@7T$S$BH=RM0>>9@A&+( VK^7&R;W:?*8MZ7'K2OWS6F&N C"N$AS6.P
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MWF<HOSZ_X^S?O2P/@\%P1*H4!BK[QN5G3UMQ[9%?IER#XNI(K*YU*S:-)C]
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M5D?W]/14\^\J9[\ X'<;M%@2ZH*@]UP2TZ_;DF3\-U5D5/DEM=M3^]T. U,
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M1FE/>EG+])+Q"RY]/O#%BGV ^QVP+!3^#)IUQ#%7?%X#A11J$@GW55C7GB=
M19M(<I+D?/;C/_28G:966OX\8-@_A[G82_%7+"^XCWEF241@#'*[9 2H#"Y
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MX:?Q4&MEVDT/N+_0OCW=J&AT$B#)^O."%]FBZ<%0JZH4:DD]TT(ZS(4JDZF
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M0@L"O?GLFGF\EG0?KLVM3UG'P)5G)-B%P>RTL6C,[:CA#C5(ZN,E]9J&,6Z
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MIKZT?S*L6G':]<?LM2 >))@CF-M/%ML_F&LZ[<H1L2!YV@]'53\-Q91+;Z5
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M,# Q-3,T,3,S+3(P,C4P,S(W+FAT;5!+ 0(4 Q0    ( ,,[>UI_C:X5X0@
M *AE   9              "  3H4  !C:S P,#$U,S0Q,S,M,C R-3 S,C<N
M>'-D4$L! A0#%     @ PSM[6K.ZM\FW)P  ELX" !<              ( !
M4AT  &-K,# P,34S-#$S,RUE>#DY7S$N:'1M4$L%!@     #  , TP   #Y%
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ck0001534133-20250327_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ck0001534133-20250327.xsd" xlink:type="simple"/>
    <context id="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
        </entity>
        <period>
            <startDate>2025-03-27</startDate>
            <endDate>2025-03-27</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_265d8cb2-1445-471f-8432-7ff8b7624fc9">0001534133</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_de3710dc-e6db-4a09-ad63-a2b8e0102b44">false</dei:AmendmentFlag>
    <dei:SecurityExchangeName
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_bcfb88c7-791f-4349-8638-5d1e4d9827f8">NONE</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_7aedebb8-67e5-461d-a4ab-a2ccbac6ad1b">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_d5bef944-5f6f-46dc-8aec-016faa459175">2025-03-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_c0170a5b-da27-4cf1-ae25-0054ad12caca">CalciMedica, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_b4f12da2-08bf-445f-8d62-8f92ab44e5e5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_2ed06d9a-7633-4833-a181-454c1b5a180f">001-39538</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_1ba79f07-19fe-4adb-9bad-2fd6dabc7982">45-2120079</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_62dbdf2e-f723-40f3-b3bd-1c2e679d8159">505 Coast Boulevard South, Suite 307</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_6d455063-c512-4894-a9a8-eee236194afb">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_f4dc6bb9-af4c-4830-8dd8-67bb0e635c8c">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_5b084aa3-3056-4452-b769-88f253a02229">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_04ac3a63-3b25-4bc2-b1db-1468c042a381">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_6c886ca3-94f9-4289-bc05-ad325e81281e">952-5500</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_f3f2892f-a9be-4e60-9f15-9c62079fc036">Not Applicable</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_ab3c04f4-da5a-42bc-b794-5698ddfff292">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_901acf24-a0e9-4d3c-9e78-081b8e41d9b4">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_406e7715-9d36-4d0f-af2e-015410a21ee9">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_87c87279-90b6-46de-bfe2-c0496d6543ed">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_b1275da8-8f05-45e5-9242-d6ce9e81860e">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_b047843e-7887-411e-aac7-d797dcf7aad6">CALC</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_17551bc6-0df0-4d90-ab0a-2b2cef9fd39d">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_0f8b28e1-5728-4a79-b40b-70f4f11ab0be"
      id="F_49eca329-7e58-4520-82ea-11130916fe2f">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
